The aim of the present study was to compare the expression levels of serum GP73 in control and patient groups of individuals with liver diseases, including chronic hepatitis, liver cirrhosis and HCC, to evaluate and investigate the diagnostic value and accuracy of measuring serum GP73 in combination with AFP and GGT-II in HCC patients. The gene discussed is GOLM1; the disease is hepatocellular carcinoma.